[1]罗晓雅,杨志宏.肠道菌群与心血管疾病相关性的研究进展[J].中国药理学通报,2018,(08):1037-1041.[doi:10.3969/j.issn.1001-1978.2018.08.001]
 LUO Xiao-ya,YANG Zhi-hong.Research progress on correlation between intestinal flora and cardiovascular diseases[J].Chinese Pharmacological Bulletin,2018,(08):1037-1041.[doi:10.3969/j.issn.1001-1978.2018.08.001]
点击复制

肠道菌群与心血管疾病相关性的研究进展()
分享到:

《中国药理学通报》[ISSN:/CN:]

卷:
期数:
2018年08期
页码:
1037-1041
栏目:
讲座与综述
出版日期:
2018-07-26

文章信息/Info

Title:
Research progress on correlation between intestinal flora and cardiovascular diseases
文章编号:
1001-1978(2018)08-1037-05
作者:
罗晓雅杨志宏
中国医学科学院北京协和医学院药用植物研究所药理毒理中心,北京 100193
Author(s):
LUO Xiao-ya YANG Zhi-hong
Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences & Peking Union Medical College; Center of Pharmacology and Toxicology, Beijing 100193,China
关键词:
肠道菌群 紊乱 心血管疾病 相关性 干预治疗 研究进展
Keywords:
intestinal flora disorder cardiovascular disease relevance intervention therapy research progress
分类号:
R-05; R322.45; R378.2; R540.5
DOI:
10.3969/j.issn.1001-1978.2018.08.001
文献标志码:
A
摘要:
肠道菌群是调节宿主代谢活动及调控肠道免疫屏障和生物屏障的重要微生物群,与心血管疾病联系密切。肠道菌群紊乱可破坏机体正常代谢,增强体内氧化应激反应,并通过内毒素移位到体循环而加剧全身性炎症,是心血管疾病发生、发展的重要因素之一。而心血管疾病患者血流动力学的变化可进一步改变其肠道的形态、功能以及肠道菌群组成,从而造成疾病恶化。该文通过检索、梳理近16年国内外相关文献,综述肠道菌群与心血管疾病的相互作用机制,以及通过肠道菌群治疗心血管疾病的可能方法,为通过干预肠道菌群治疗心血管疾病提供理论依据和策略参考。
Abstract:
The variation in the hemodynamics of patients with cardiovascular diseases can change intestinal morphology, intestinal permeability, intestinal barrier function and intestinal flora composition.The changes can further damage the intestinal tract, resulting in intestinal flora disorders, metabolic destruction, enhancement of oxidative stress and exacerbation of systemic inflammation.Meanwhile, metabolites via intestinal flora also have a possible regulatory mechanism for the pathophysiology of cardiovascular diseases.In the review, the relevant literatures in recent 16 years concerning the interactive relationship between intestinal flora and cardiovascular diseases and treatment of cardiovascular diseases through intestinal flora have been collected, in order to provide a theoretical reference for treatment of cardiovascular diseases via intestinal flora.

参考文献/References:

[1] Coyte K Z, Schluter J, Foster K R.The ecology of the microbiome:networks, competition, and stability[J].Science, 2015, 350(6261):663-6.
[2] Nagatomo Y, Tang W H.Intersections between microbiome and heart failure:revisiting the gut hypothesis[J].J Card Fail, 2015, 21(12):973-80.
[3] Rogler G, Rosano G.The heart and the gut[J].Eur Heart J, 2014, 35(7):426-30.
[4] 吕俊平, 王树人, 马增春, 等.运用蛋白质组学技术研究TNF-α对血管内皮细胞的作用机制[J].中国病理生理杂志, 2004, 20(7):1121-5.
[4] Lyu J P, Wang S R, Ma Z C, et al.Proteomic analysis of the effects of tumor necrosis factor-α on endothelial cells[J].Chin J Pathophysiol, 2004,20(7):1121-5.
[5] Yang J X, Pan Y Y, Ge J H, et al.Tanshinone II A attenuates TNF-α-induced expression of VCAM-1 and ICAM-1 in endothelial progenitor cells by blocking activation of NF-κB[J].Cell Physiol Biochem, 2016, 40(1-2):195-206.
[6] Cani P D, Bibiloni R, Knauf C, et al.Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice[J].Diabetes, 2008, 57(6):1470-81.
[7] Bäckhed F, Ding H, Wang T, et al.The gut microbiota as an environmental factor that regulates fat storage[J].Proc Natl Acad Sci USA, 2004, 101(44):15718-23.
[8] Ierardi E, Sorrentino C, Principi M, et al.Intestinal microbial metabolism of phosphatidylcholine:a novel insight in the cardiovascular risk scenario[J].Hepatobiliary Surg Nutr, 2015, 4(4):289-92.
[9] Sun Q, Dong Y, Wang H, et al.Antiperoxynitrite treatment ameliorates vasorelaxation of resistance arteries in aging rats:involvement with protection of circulating endothelial progenitor cells[J].J Cardiovasc Pharmacol, 2016, 68(5):334-41.
[10] 严春琳, 杨 静, 韩际宏, 等.中药抗动脉粥样硬化机制研究进展[J].中国药理学与毒理学杂志, 2014, 28(6):904-13.
[10] Yan C L, Yang J, Han J H, et al.Advances in anti-atherosclerosis mechanisms of traditional Chinese medicine[J].Chin J Pharmacol Toxicol, 2014, 28(6):904-13.
[11] Lekawanvijit S, Adrahtas A, Kelly D J, et al.Does indoxyl sulfate, a uraemic toxin, have direct effects on cardiac fibroblasts and myocytes[J].Eur Heart J, 2010, 31(14):1771-9.
[12] 钱 乾.TLR13和肠道菌群在柯萨奇病毒性心肌炎发病中的作用及其机制[D].苏州:苏州大学, 2014.
[12] Qian Q.Role of TLR13 and microflora in the pathogenesis of CVB3-induced myocarditis[D].Suzhou:Soochow University, 2014.
[13] 张 烽, 张晨虹.膳食营养与肠道微生物组[J].生命科学, 2017, 29(7):695-706.
[13] Zhang F, Zhang C H.Dietary nutrition and gut microbiota[J].Chin Bull Life Sci, 2017, 29(7):695-706.
[14] Lam V, Su J, Koprowski S, et al.Intestinal microbiota determine severity of myocardial infarction in rats[J].FASEB J, 2012, 26(4):1727-35.
[15] Conraads V M, Jorens P G, De Clerck L S, et al.Selective intestinal decontamination in advanced chronic heart failure:a pilot trial[J].Eur J Heart Fail, 2004, 6(4):483-91.
[16] 姜明明, 方 强, 孙 勤, 等.添加益生菌的早期肠内营养对重型颅脑损伤患者血清炎症因子与肠黏膜屏障功能的影响[J].中国微生态学杂志, 2015, 27(10):1177-80.
[16] Jiang M M, Fang Q, Sun Q, et al.Influence of early enteral nutrition with added probiotics on serum inflammatory factors and intestinal mucous membrane barrier function of patients with severe brain injury[J].Chin J Microecol, 2015, 27(10):1177-80.
[17] Gan X T, Ettinger G, Huang C X, et al.Probiotic administration attenuates myocardial hypertrophy and heart failure after myocardial infarction in the rat[J].Circ Heart Fail, 2014, 7(3):491-9.
[18] Ren Z H, Tong Y H, Xu W, et al.Tanshinone II A attenuates inflammatory responses of rats with myocardial infarction by reducing MCP-1 expression[J].Phytomedicine, 2010, 17(3-4):212-8.
[19] 林 超, 刘兆国, 钱 星, 等.丹酚酸B在心血管疾病中药理作用研究进展[J].中国药理学通报, 2015, 31(4):449-52.
[19] Lin C, Liu Z G, Qian X, et al.Research progress of salvianolic acid B in cardiovascular diseases[J].Chin Pharmacol Bull, 2015, 31(4):449-52.
[20] 陈 健,黄 玲,李 岩, 等.黄芩苷对脂多糖诱导的肠道上皮细胞凋亡及迁移能力的影响[J].广州中医药大学学报, 2015, 32(1):126-9.
[20] Chen J, Huang L, Li Y, et al.Effect of baicalin on the apoptosis and migration of intestinal epithelial cells induced by lipopolysaccharide[J].J Guangzhou Univ Tradit Chin Med, 2015, 32(1):126-9.
[21] 王 彪, 袁海军, 袁 娜, 等.野黄芩素对内毒素血症大鼠急性肺损伤的保护作用[J].中国现代医学杂志, 2016, 26(12):15-20.
[21] Wang B, Yuan H J, Yuan N, et al.Protective effect of scutellarein on acute lung injury in endotoxemic rats[J].Chin J Mod Med, 2016, 26(12):15-20.
[22] Zhang B Q, Hu S J, Qiu L H, et al.Effects of Astragalus membranaceus and its main components on the acute phase endothelial dysfunction induced by homocysteine[J].Vascul Pharmacol, 2007, 46(4):278-85.
[23] Wang D, Zhuang Y, Tian Y, et al.Study of the effects of total flavonoids of Astragalus on atherosclerosis formation and potential mechanisms[J].Oxid Med Cell Longev, 2012, 2012:282383.
[24] 张 宇, 沈 宇, 胡新俊, 等.黄芪多糖对微生态调节作用的物质基础研究初探[J].中国微生态学杂志, 2012, 24(2):113-6.
[24] Zhang Y, Shen Y,Hu X J, et al.Research on material bases of microecological adjustment of Astragalus polysaccharides[J].Chin J Microecol, 2012, 24(2):113-6.
[25] 刘艳艳, 张 凯, 关家伟, 等.人参皂苷对BALB/c小鼠肠道菌群的影响[J].现代生物医学进展, 2015, 15(6):1041-5.
[25] Liu Y Y, Zhang K, Guan J W, et al.The effects of ginsenoside on the intestinal microbiota of mice[J].Prog Mod Biomed, 2015, 15(6):1041-5.

相似文献/References:

[1]林慧敏,庞杰,范琳琳,等.魔芋葡甘聚糖免疫活性研究进展[J].中国药理学通报,2010,(11):1404.
 LIN Hui min,PANG Jie,FAN Lin lin,et al.Advances in immunological activities of Konjac glucomannan[J].Chinese Pharmacological Bulletin,2010,(08):1404.
[2]吴夏飞,等.肠道菌群对慢性肝脏疾病影响的研究进展[J].中国药理学通报,2013,(12):1644.
 WU Xia-fei,LIAN Na-qi,LU Chun-feng,et al.Research progress on effect of intestinal flora on chronic liver diseases[J].Chinese Pharmacological Bulletin,2013,(08):1644.
[3]王 生,黄晓星,余鹏飞,等.肠道菌群失调与结肠癌发生发展之间关系的研究进展[J].中国药理学通报,2014,(08):1045.
 WANG Sheng,HUANG Xiao-xing,YU Peng-fei,et al.Intestinal microbiota dysbiosis associated with the development of colon cancer: progress and prospects[J].Chinese Pharmacological Bulletin,2014,(08):1045.
[4]臧 月,王 生,刘 楠,等.肠道菌群失调介导酒精性肝病发生发展的机制研究进展[J].中国药理学通报,2016,(04):451.[doi:10.3969/j.issn.1001-1978.2016.04.002]
 ZANG Yue,WANG Sheng,LIU Nan,et al.Alcoholic liver disease: gut microbiota and therapeutic perspectives[J].Chinese Pharmacological Bulletin,2016,(08):451.[doi:10.3969/j.issn.1001-1978.2016.04.002]

备注/Memo

备注/Memo:
收稿日期:2018-04-10,修回日期:2018-05-15
基金项目:国家自然科学基金资助项目(No 81473579,81273654,81102879); 北京市自然科学基金资助项目(No 7173267); 国家科技部“重大新药创制”科技重大专项(No 2013ZX09103002-022)
作者简介:罗晓雅(1994-),女,硕士生,研究方向:中药药物代谢,E-mail:18804897936@163.com;
杨志宏(1976-),女,博士,副研究员,硕士生导师,研究方向:中药药物代谢,通讯作者,E-mail:zhyang@implad.ac.cn
更新日期/Last Update: 2018-07-26